Research progress of tirofiban in the treatment of ruptured intracranial aneurysms

doi:10.12092/j.issn.1009-2501.2026.01.012

Abstract

Abstract:

Ruptured intracranial aneurysm is a cerebrovascular emergency with high mortality and morbidity. Although stent-assisted coil embolization is effective, complications such as intraoperative thrombosis and postoperative bleeding remain prominent issues. Tirofiban, a potent platelet aggregation inhibitor, with its rapid onset, short half-life, and quick recovery of platelet function, shows potential in the treatment of ruptured intracranial aneurysms. This review summarizes the pharmacological mechanisms of tirofiban and its clinical applications, analyzes its efficacy and safety at different doses, and explores its rational use in preoperative prophylaxis and intraoperative salvage therapy. Furthermore, the review discusses the challenges and limitations of using tirofiban in the treatment of ruptured intracranial aneurysms and proposes future research directions. The goal is to provide evidence-based support for the standardized application of tirofiban and enhance its value in neurointerventional therapy.

Key words: tirofiban, ruptured intracranial aneurysm, stent-assisted coil, flow diverter, low dose

CLC Number:

R543.1

Li YANG, Zhi ZHENG, Xufeng MENG, Qian LIU, Yunfei HAO. Research progress of tirofiban in the treatment of ruptured intracranial aneurysms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 107-115.

Figures/Tables 2

References 71

1	Frösen J, Tulamo R, Paetau A, et al. Saccular intracranial aneurysm: pathology and mechanisms[J]. Acta Neuropathol, 2012, 123 (6): 773- 786. doi: 10.1007/s00401-011-0939-3
2	Chalouhi N, Hoh BL, Hasan D. Review of cerebral aneurysm formation, growth, and rupture[J]. Stroke, 2013, 44 (12): 3613- 3622. doi: 10.1161/STROKEAHA.113.002390
3	Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis[J]. Lancet Neurol, 2009, 8 (7): 635- 642. doi: 10.1016/S1474-4422(09)70126-7
4	Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review[J]. Neurology, 2010, 74 (19): 1494- 1501. doi: 10.1212/WNL.0b013e3181dd42b3
5	宋英, 刘健, 张亮, 等. 极早期血管内治疗颅内破裂动脉瘤的临床疗效评价[J]. 长春中医药大学学报, 2024, 40 (9): 1024- 1027. doi: 10.13463/j.cnki.cczyy.2024.09.019
6	覃星悦, 陈圣昌, 秦柱贵, 等. CT及磁共振血管成像诊断颅内动脉瘤的价值[J]. 长春中医药大学学报, 2024, 40 (5): 566- 570.
7	Lodi YM, Latorre JG, El-zammar Z, et al. Stent assisted coiling of the ruptured wide necked intracranial aneurysm[J]. J Neurointerv Surg, 2012, 4 (4): 281- 286. doi: 10.1136/neurintsurg-2011-010035
8	Zhang X, Zuo Q, Tang H, et al. Stent assisted coiling versus non-stent assisted coiling for the management of ruptured intracranial aneurysms: a meta-analysis and systematic review[J]. J Neurointerv Surg, 2019, 11 (5): 489- 496. doi: 10.1136/neurintsurg-2018-014388
9	Choi HH, Cho YD, Han MH, et al. Antiplatelet premedication-free stent-assisted coil embolization in acutely ruptured aneurysms[J]. World Neurosurg, 2018, 114, e1152- e1160. doi: 10.1016/j.wneu.2018.03.164
10	Tähtinen OI, Vanninen RL, Manninen HI, et al. Wide-necked intracranial aneurysms: treatment with stent-assisted coil embolization during acute (<72 hours) subarachnoid hemorrhage--experience in 61 consecutive patients [J]. Radiology, 2009, 253(1): 199-208.
11	Kim YH, Kim CH, Lee SW, et al. Clinical safety and efficacy of stent-assisted coil embolization with ACCERO stent in cerebral aneurysm: Short-term follow-up and precaution for use [J]. J Cerebrovasc Endovasc Neurosurg, 2025, doi: 10.7461/jcen.2025.E2025.02.002.
12	Chen SD, Yang CB, Wang YX, et al. Safety and efficacy of endovascular embolization combined with external drainage for poor-grade ruptured cerebral aneurysms[J]. ANZ J Surg, 2025, 95 (5): 972- 978. doi: 10.1111/ans.19349
13	Settipalli KP, Dunkerton S, Hilton J, et al. The ELVIS study: Medium and long-term Efficacy of LVIS EVO stent-assisted coil embolisation for unruptured saccular intracranial aneurysms-A tertiary single-centre experience[J]. J Med Imaging Radiat Oncol, 2024, 69 (2): 212- 220.
14	黄品芳, 潘冠星, 张菁. 抗血小板药物临床应用现状及研发新进展[J]. 中国临床药理学与治疗学, 2025, 30 (1): 91- 99.
15	Kim S, Choi JH, Kang M, et al. Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms[J]. AJNR Am J Neuroradiol, 2016, 37 (3): 508- 514. doi: 10.3174/ajnr.A4551
16	贺晓武, 左乔, 黄清海, 等. 不同剂量替罗非班在支架辅助栓塞颅内破裂动脉瘤中的应用比较[J]. 中国脑血管病杂志, 2018, 15 (10): 505- 551. doi: 10.3969/j.issn.1672-5921.2018.10.001
17	Osgood ML. Aneurysmal Subarachnoid Hemorrhage: Review of the Pathophysiology and Management Strategies[J]. Curr Neurol Neurosci Rep, 2021, 21 (9): 50. doi: 10.1007/s11910-021-01136-9
18	Tawk RG, Hasan TF, D’souza CE, et al. Diagnosis and treatment of unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage[J]. Mayo Clin Proc, 2021, 96 (7): 1970- 2000. doi: 10.1016/j.mayocp.2021.01.005
19	Sharifi-rad J, Sharopov F, Ezzat SM, et al. An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives[J]. High Blood Pressure Cardiovascular Prevention, 2023, 30 (2): 93- 107. doi: 10.1007/s40292-023-00562-9
20	Bennett JS. αIIbβ3 (GPIIb/IIIa) Structure and Function [M]//Gresele P, Kleiman NS, Lopez JA, et al. Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an Update. Cham; Springer International Publishing. 2017: 99-112.
21	Chatterjee M. GPIIb/IIIa-GPVI–commanded platelet patrol[J]. Blood, 2022, 140 (2): 81- 83. doi: 10.1182/blood.2022016697
22	杨橹, 熊晔, 黄建荣. 人血白蛋白在终末期肝病中的应用[J]. 临床肝胆病杂志, 2022, 38 (4): 936- 941. doi: 10.3969/j.issn.1001-5256.2022.04.040
23	Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?[J]. Circulation, 1999, 100 (4): 437- 444. doi: 10.1161/01.CIR.100.4.437
24	Yang M, Huo X, Miao Z, et al. Platelet Glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke[J]. Drugs, 2019, 79 (5): 515- 529. doi: 10.1007/s40265-019-01078-0
25	Bernava G, Meling TR, Rosi A, et al. Acute stenting and concomitant tirofiban administration for the endovascular treatment of acute ischemic stroke related to intracranial artery dissections: a single center experience and systematic review of the literature[J]. J Stroke Cerebro Dis, 2021, 30 (8): 105891. doi: 10.1016/j.jstrokecerebrovasdis.2021.105891
26	Wang M, Li J, Zhang L, et al. The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis[J]. Front Neurol, 2024, 15, 1286079. doi: 10.3389/fneur.2024.1286079
27	Ribeiro LFS, De freitas LR, Udoma-udofa OC, et al. Efficacy and safety of tirofiban in acute ischemic stroke due to intracranial atherosclerotic disease for patients undergoing endovascular treatment: a systematic review and meta-analysis[J]. Neuroradiol, 2025, 67 (1): 241- 255. doi: 10.1007/s00234-024-03537-2
28	Al-salihi MM, Ayyad A, Al-jebur MS, et al. Safety and efficacy of tirofiban in the management of stroke: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Neurol Neurosurg, 2023, 232, 107867. doi: 10.1016/j.clineuro.2023.107867
29	霍晓川, 缪中荣. 《替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识》解读[J]. 中国现代神经疾病杂志, 2020, 20 (5): 381- 385. doi: 10.3969/j.issn.1672-6731.2020.05.003
30	Li X, Zhang S, Wang Z, et al. Platelet function and risk of bleeding in patients with acute coronary syndrome following tirofiban infusion[J]. Front Pharmacol, 2019, 10, 1158. doi: 10.3389/fphar.2019.01158
31	Pierot L, Cognard C, Anxionnat R, et al. Ruptured intracranial aneurysms: factors affecting the rate and outcome of endovascular treatment complications in a series of 782 patients (CLARITY study)[J]. Radiol, 2010, 256 (3): 916- 923. doi: 10.1148/radiol.10092209
32	Chalouhi N, Jabbour P, Singhal S, et al. Stent-assisted coiling of intracranial aneurysms: predictors of complications, recanalization, and outcome in 508 cases[J]. Stroke, 2013, 44 (5): 1348- 1353. doi: 10.1161/STROKEAHA.111.000641
33	Yamada NK, CRoss DT, 3RD, Pilgram TK, et al. Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms[J]. AJNR Am J Neuroradiol, 2007, 28 (9): 1778- 1782. doi: 10.3174/ajnr.A0641
34	Ries T, Buhk JH, Kucinski T, et al. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events[J]. Stroke, 2006, 37 (7): 1816- 1821. doi: 10.1161/01.STR.0000226933.44962.a6
35	Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention[J]. Circulation, 2005, 111 (20): 2560- 2564. doi: 10.1161/01.CIR.0000160869.75810.98
36	El rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine[J]. Expert Opin Drug Metab Toxicol, 2018, 14 (4): 447- 460. doi: 10.1080/17425255.2018.1461835
37	中国医师协会神经介入专业委员会, 中国颅内动脉瘤计划研究组. 中国颅内破裂动脉瘤诊疗指南2021[J]. 中国脑血管病杂志, 2021, 18 (8): 546- 574.
38	Ziliang W, Xiaodong L, Tianxiao L, et al. Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms[J]. Int J Stroke, 2017, 12 (5): 553- 559. doi: 10.1177/1747493016677989
39	Shen G, Jia Z, Zhao L, et al. The safety and efficacy of a low dose of tirofiban for early complications during and after stent-assisted coiling of ruptured intracranial aneurysms: A propensity matching study[J]. Clin Neurol Neurosurg, 2022, 214, 107132. doi: 10.1016/j.clineuro.2022.107132
40	Xiang Y, Zhao H, Ding C, et al. The prophylactic use of tirofiban versus oral antiplatelet medications in stent-assisted coiling of intracranial aneurysms: a meta-analysis[J]. AJNR Am J Neuroradiol, 2021, 42 (4): 713- 719. doi: 10.3174/ajnr.A6996
41	Oliveira M, Jesus AC, Moro I, et al. Abstract TMP35: comparative effect of tirofiban vs dual antiplatelet therapy or aspirin alone on neurological deterioration in patients with ischemic stroke: a systematic review and meta-analysis[J]. Stroke, 2025, 56 (Suppl_1): ATMP35- ATMP. doi: 10.1161/str.56.suppl_1.tmp35
42	Riscado LVS, De pinho JHS, Lobato AC. Efficacy and safety of tirofiban bridge as an alternative to suspension of dual antiplatelet therapy in patients undergoing surgery: a systematic review[J]. J Vasc Bras, 2021, 20, e20210113.
43	Guo YZ, Zhao ZW, Li SM, et al. Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI[J]. Scientific Reports, 2021, 11 (1): 17144. doi: 10.1038/s41598-021-96606-y
44	Wang KS, Chen YJ, Xu Y, et al. Perioperative complications of arteriovenous tirofiban administration versus oral dual antiplatelet therapy for stent-assisted embolization treated aneurysmal subarachnoid hemorrhage: a retrospective, controlled cohort analysis [J]. Brain Behav, 2024, 14 (6): e3439.
45	Lordkipanidzé M, So D, Tanguay JF. Platelet function testing as a biomarker for efficacy of antiplatelet drugs[J]. Biomark Med, 2016, 10 (8): 903- 918. doi: 10.2217/bmm-2016-0070
46	Rocca B, Patrono C. Precision antiplatelet therapy[J]. Res Prac Thromb Haem, 2023, 7 (3): 100138. doi: 10.1016/j.rpth.2023.100138
47	Bećirović E, Ljuca K, Bećirović M, et al. Prognostic value of a decrease in mean platelet volume, platelet distribution width, and platelet-large cell ratio for major adverse cardiovascular events after myocardial infarction without ST-segment elevation: an observational study[J]. Biomol Biomed, 2023, 23 (5): 866- 872. doi: 10.17305/bb.2023.9178
48	Lee SH, Park IS, Lee JM, et al. Stent-assisted coil embolization using only a glycoprotein IIb/IIIa inhibitor (Tirofiban) for ruptured wide-necked aneurysm repair[J]. J Cerebrovasc Endovasc Neurosurg, 2018, 20 (1): 14- 23. doi: 10.7461/jcen.2018.20.1.14
49	Li W, Li N, Miao Q, et al. Application of tirofiban for stent-assisted coiling in acutely ruptured intracranial aneurysms [C]. Proceedings of the 2022 12th International Conference on Information Technology in Medicine and Education (ITME), 2022.
50	Liang X, Wang ZL, Li TX, et al. Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms[J]. J NeuroInt Surg, 2015, 8 (11): 1148- 1153. doi: 10.1136/neurintsurg-2015-012055
51	Sayin B, Karaman A, Balci S, et al. Dual stenting with new-generation stents for aneurysm embolization in acute subarachnoid hemorrhage[J]. World Neurosurg, 2021, 154, e102- e108. doi: 10.1016/j.wneu.2021.06.135
52	Ma Y, Jia C, Zhang T, et al. Safety and efficacy of intravenous tirofiban for stent-assisted coiling in acutely ruptured intracranial aneurysms: a single center experience[J]. Interv Neuroradiol, 2022, 28 (4): 476- 481. doi: 10.1177/15910199211042463
53	Yan Y, He X, Fang Y, et al. The safety and efficacy of low-dosage tirofiban for stent-assisted coiling of ruptured intracranial aneurysms[J]. Neurosurg Rev, 2021, 44 (4): 2211- 2218. doi: 10.1007/s10143-020-01398-w
54	Feng L, Chen J, Lv CF, et al. Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms[J]. Turk Neurosurg, 2014, 24 (6): 929- 936. doi: 10.5137/1019-5149.jtn.12006-14.1
55	Kang HS, Kwon BJ, Roh HG, et al. Intra-arterial tirofiban infusion for thromboembolism during endovascular treatment of intracranial aneurysms[J]. Neurosurgery, 2008, 63 (2): 230- 237. doi: 10.1227/01.NEU.0000320440.85178.CC
56	Cho YD, Lee JY, Seo JH, et al. Intra-arterial tirofiban infusion for thromboembolic complication during coil embolization of ruptured intracranial aneurysms[J]. Eur J Radiol, 2012, 81 (10): 2833- 2838. doi: 10.1016/j.ejrad.2011.11.023
57	Jeong HW, Jin SC. Intra-arterial infusion of a glycoprotein IIb/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban[J]. AJNR Am J Neuroradiol, 2013, 34 (8): 1621- 1625. doi: 10.3174/ajnr.A3501
58	Wang J, Zou D. Tirofiban-induced thrombocytopenia[J]. Ann Med, 2023, 55 (1): 2233425. doi: 10.1080/07853890.2023.2233425
59	Yang C, Liao Y, Peng G, et al. Onyx prevents the bleeding of ruptured aneurysms during interventional embolization[J]. Neuro Rev, 2024, 47 (1): 770. doi: 10.1007/s10143-024-02953-5
60	贾媛, 白世茹, 李如意, 等. 血小板功能检测的常用方法及容易忽略的影响因素[J]. 中国心血管杂志, 2020, 25 (2): 197- 200.
61	Gurney D. Platelet function testing: from routine to specialist testing[J]. Br J Biomed Sci, 2016, 73 (1): 10- 20. doi: 10.1080/09674845.2016.1156865
62	Paniccia R, Priora R, Liotta AA, et al. Platelet function tests: a comparative review[J]. Vasc Health Risk Manag, 2015, 11, 133- 148. doi: 10.2147/vhrm.s44469
63	Kellert L, Hametner C, Rohde S, et al. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome[J]. Stroke, 2013, 44 (5): 1453- 1455. doi: 10.1161/STROKEAHA.111.000502
64	卜香叶, 夏文卿, 蒋琳, 等. 替罗非班在后循环大动脉闭塞性脑梗死机械取栓术中的应用[J]. 浙江临床医学, 2022, 24 (2): 176- 178.
65	Gong J, Shang J, Yu H, et al. Tirofiban for acute ischemic stroke: systematic review and meta-analysis[J]. Euro J Clin Pharmacol, 2020, 76 (4): 475- 481. doi: 10.1007/s00228-019-02817-8
66	Zhu X, Guo Z, Tian L, et al. Efficacy and safety of tirofiban combined with endovascular therapy for basilar artery occlusion stroke due to large artery atherosclerosis[J]. J Stroke Cerebrovas Dis, 2024, 33 (2): 107526. doi: 10.1016/j.jstrokecerebrovasdis.2023.107526
67	Sun Y, Guo ZN, Yan X, et al. Safety and efficacy of tirofiban combined with endovascular therapy compared with endovascular therapy alone in acute ischemic stroke: a meta-analysis[J]. Neuroradiology, 2021, 63 (1): 17- 25. doi: 10.1007/s00234-020-02530-9
68	Tigen MK, Özdil MH, Çinçin A, et al. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: a real-life data[J]. Anatol J Cardiol, 2021, 25 (10): 699- 705. doi: 10.5152/AnatolJCardiol.2021.27974
69	郝静, 赵娜, 孔孟丹, 等. 替罗非班治疗进展性缺血性卒中的疗效和安全性观察[J]. 解放军医学院学报, 2017, 38 (5): 409- 413.
70	阿布都喀哈尔·阿布都拉, 哈力木拉提·吾布力卡斯木, 段绍斌. 胆道支架的研究现状[J]. 临床肝胆病杂志, 2023, 39 (10): 2491- 2496. doi: 10.3969/j.issn.1001-5256.2023.10.031
71	姚欣, 周昊, 汤善宏, 等. 肝硬化门静脉高压患者行经颈静脉肝内门体分流术术中置入Viatorr支架分流门静脉左、右支血流对疗效的影响[J]. 临床肝胆病杂志, 2020, 36 (9): 1970- 1974.

研究/团队	样本量（n）	给药方案	并发症	主要发现
Lee等^[48]	50	静脉负荷0.4 μg·kg^?1·min^?1（30 min），随后25 μg/kg维持23.5 h	5例血栓形成，2例延迟出血事件	高剂量有效抑制血小板聚集，但与延迟出血风险相关
Li等^[49]	46	静脉负荷10 μg/kg（3 min），随后 0.1 μg·kg^?1·min^?1维持12 h	2例术后血栓事件，2例胃肠道出血	较低的血栓事件发生率，但仍有出血事件发生
梁晓东等^[50]	175	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	6例血栓栓塞事件，4例替罗非班相关出血事件	中等剂量显示一定疗效，但伴随较高出血风险
王子良等^[38]	128	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	5例血栓事件，未见明显出血事件	安全性较高，血栓事件发生较少
Sayin等^[51]	16	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	2例血栓形成	样本量较小，但表明中等剂量使用安全
马一辉等^[52]	105	静脉负荷5 μg/kg，随后0.06～ 0.08 μg·kg^?1·min^?1维持6～8 h	无出血事件，3例血栓栓塞事件	低剂量替罗非班安全有效，未发生出血并发症
闫亚洲等^[53]	309	标准组：静脉负荷10 μg/kg（3 min），随后0.15 μg·kg^?1·min^?1维持6～8 h；半剂量组：静脉负荷5 μg/kg（3 min），随后0.075 μg·kg^?1·min^?1维持6～8 h	15例血栓栓塞事件（标准组：11例，半剂量组：4例），13例出血事件（全部为标准剂量组）	标准剂量组血栓和出血发生率较高，半剂量组较低
沈咣晨等^[39]	72	静脉负荷5 μg/kg（1 min），随后 0.1 μg·kg^?1·min^?1维持	4.17%的血栓并发症，1例出血并发症	低剂量方案显示出良好的血栓控制效果，出血事件较少
Kim等^[15]	41	静脉负荷0.4 μg·kg^?1·min^?1（30 min），随后0.1 μg·kg^?1·min^?1维持	无出血事件	低剂量替罗非班有效且无出血并发症

研究/团队	样本量（n）	给药方案	并发症	主要发现
Lee等^[48]	50	静脉负荷0.4 μg·kg^?1·min^?1（30 min），随后25 μg/kg维持23.5 h	5例血栓形成，2例延迟出血事件	高剂量有效抑制血小板聚集，但与延迟出血风险相关
Li等^[49]	46	静脉负荷10 μg/kg（3 min），随后 0.1 μg·kg^?1·min^?1维持12 h	2例术后血栓事件，2例胃肠道出血	较低的血栓事件发生率，但仍有出血事件发生
梁晓东等^[50]	175	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	6例血栓栓塞事件，4例替罗非班相关出血事件	中等剂量显示一定疗效，但伴随较高出血风险
王子良等^[38]	128	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	5例血栓事件，未见明显出血事件	安全性较高，血栓事件发生较少
Sayin等^[51]	16	静脉负荷8 mg/kg（3 min），随后 0.1 mg·kg^?1·min^?1维持	2例血栓形成	样本量较小，但表明中等剂量使用安全
马一辉等^[52]	105	静脉负荷5 μg/kg，随后0.06～ 0.08 μg·kg^?1·min^?1维持6～8 h	无出血事件，3例血栓栓塞事件	低剂量替罗非班安全有效，未发生出血并发症
闫亚洲等^[53]	309	标准组：静脉负荷10 μg/kg（3 min），随后0.15 μg·kg^?1·min^?1维持6～8 h；半剂量组：静脉负荷5 μg/kg（3 min），随后0.075 μg·kg^?1·min^?1维持6～8 h	15例血栓栓塞事件（标准组：11例，半剂量组：4例），13例出血事件（全部为标准剂量组）	标准剂量组血栓和出血发生率较高，半剂量组较低
沈咣晨等^[39]	72	静脉负荷5 μg/kg（1 min），随后 0.1 μg·kg^?1·min^?1维持	4.17%的血栓并发症，1例出血并发症	低剂量方案显示出良好的血栓控制效果，出血事件较少
Kim等^[15]	41	静脉负荷0.4 μg·kg^?1·min^?1（30 min），随后0.1 μg·kg^?1·min^?1维持	无出血事件	低剂量替罗非班有效且无出血并发症

[1]	TU Hanming, XU Guoqiang, CHEN Yongkang. Clinical effects of tirofiban and butylphthalide combined with stent thrombectomy in the treatment of patients with acute cerebral infarction in the ultra time window [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 398-403.
[2]	LI Yi-min, HUANG Jin, LU Zhi-ping, LI Xiang-yu, HE Sheng-hu. Effects of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1403-1406.
[3]	ZHOU Yong, HUANG Song-qun, XU Fei. Efficacy on slow bleeding and safety of using tirofiban before and during emergency PCI in patients with acute ST-segment elevation myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1268-1271.
[4]	DENG Shao-xiong, GUO Nan-ou, ZHENG-Yuan, HUANG Wen-sen. Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 807-811.
[5]	XIE Shuang-feng, YIN Song-mei, NIE Da-nian, LI Yi-qing, XIAO Jie, MA Li-ping, WANG Xiu-ju, WANG Jing-feng. Effect of tirofiban on the plasma inflammatory factors of P-selectin,IL-6 and IL-1β in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 732-736.
[6]	QIU Li-ying, YU Juan, ZHOU Yu, CHEN Chong-hong. Protective effects and mechanism of low dose aspirin on focal cerebral ischemia-reperfusion rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 659-664.